India's Sun Pharma hits record high after Brazil's approval for semaglutide
BUZZ-India's Sun Pharma hits record high after Brazil's approval for semaglutide ** Drug maker Sun Pharma's shares SUN.NS rise as much as 1.35% to a record high of 2016.80 rupees apiece
** SUN receives approval from Brazil's health regulator, ANVISA, to manufacture and market its semaglutide injection in Brazil
** Semaglutide is used in the treatment of adults with inadequately controlled type 2 diabetes, alongside diet and exercise
** Size of semaglutide injectable market in Brazil is approximately $413 million as of June 2026, according to IQVIA
** SUN says it plans to launch the product in the next few days in partnership with Brazilian firm Hypera Pharma
** "Approval marks an important step in strengthening diabetes portfolio in Brazil," says Digvijay Singh, regional head of Brazil and Latin America at SUN
** SUN shares are up 17.1% in 2026 so far, mirroring the pharma index's .NIPHARM 16.4% rise, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses